Prostate Cancer - Results from #21180

A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer - Abstract March 24, 2014

A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: A step towards practical implementation - Abstract March 24, 2014

The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy - Abstract March 24, 2014

The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy - Abstract March 24, 2014

Does family history of prostate cancer affect outcomes following radiotherapy? - Abstract March 24, 2014

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases - Abstract March 24, 2014

Maintaining and reprogramming genomic androgen receptor activity in prostate cancer - Abstract March 24, 2014

Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone - Abstract March 21, 2014

A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer - Abstract March 21, 2014

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy - Abstract March 21, 2014

A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients - Abstract March 21, 2014

Diffusion-tensor MRI at 3 T: Differentiation of central gland prostate cancer from benign prostatic hyperplasia - Abstract March 21, 2014

Chemoprevention of prostate cancer by isoflavonoids - Abstract March 21, 2014

Prostate cancer prevention: Agent development strategies - Abstract March 21, 2014

An intergenerational approach to prostate cancer education: Findings from a pilot project in the southeastern USA - Abstract March 21, 2014

Value of endorectal magnetic resonance imaging at 3T for the local staging of prostate cancer - Abstract March 21, 2014

Enzalutamide for the treatment of prostate cancer: Results and implications of the AFFIRM trial - Abstract March 21, 2014

Risk adapted chemoprevention for prostate cancer: An option? - Abstract March 20, 2014

Aspirin and prostate cancer prevention - Abstract March 20, 2014

Distinguishing indolent from aggressive prostate cancer - Abstract March 20, 2014

Page 1060 of 1447